DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/khw87f/tysabri_multiple) has announced the addition of the "Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.
PharmaPoint Drug Evaluation report, Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.
Tysabri gained FDA approval in 2004 as a monotherapy for the treatment of RRMS to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. However, Tysabri was temporarily withdrawn from the market by the manufacturer in 2005 after several reported cases of fatal John Cunningham virus (JCV)-induced progressive multifocal leukoencephalopathy (PML) in Tysabri-treated patients. Following a safety review, Tysabri was reintroduced into the global markets in 2006 under the special TOUCH restricted distribution program.
Scope
- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tysabri including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tysabri for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Tysabri (natalizumab)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
For more information visit http://www.researchandmarkets.com/research/khw87f/tysabri_multiple
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System
